Department of Cancer Epidemiology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Cancer Causes Control. 2013 Apr;24(4):795-803. doi: 10.1007/s10552-013-0162-8. Epub 2013 Feb 9.
To estimate the burden of human papillomavirus (HPV) infection among sexually active women in China.
We conducted a multi-center, population-based study between May 2006 and April 2007. A total of 4,215 women aged 17-54 years were surveyed from five geographical sites: Beijing, Shanghai, Shanxi, Henan, and Xinjiang. Direct endocervical exfoliated cells were collected from consenting participants for Sure Path liquid-based cytology (BD) and HPV testing. HPV testing was performed with Hybrid Capture II (Qiagen) with high-risk and low-risk probes, and Linear Array (Roche) was utilized for HPV genotyping.
Approximately 11 % of the study population had a cytological abnormality (ASCUS or worse). HPV prevalence in the entire study population was 14.3 % (age-standardized to the world standard female population 14.5 %). The most prevalent types found were HPV16 (2.9 %), HPV52 (1.7 %), HPV58 (1.5 %), HPV33 (1 %), and HPV18 (0.8 %). Patterns of HPV prevalence differed by age, geographic region, and cytology findings. However, HPV16 was predominant among all grades of cytological abnormalities for all areas.
Although HPV18 appeared to be less frequent among population-based samples of China, given the high prevalence of HPV 16 and 18 in high-grade squamous intraepithelial lesion (HSIL) or worse pap abnormalities, prophylactic HPV16/18 vaccines should substantially reduce the burden of cervical cancer in China.
评估中国活跃性活跃女性中人类乳头瘤病毒(HPV)感染的负担。
我们于 2006 年 5 月至 2007 年 4 月进行了一项多中心、基于人群的研究。从五个地理区域(北京、上海、山西、河南和新疆)共调查了 4215 名 17-54 岁的女性。同意的参与者直接从宫颈内收集脱落细胞进行SurePath 液基细胞学(BD)和 HPV 检测。使用 Hybrid Capture II(Qiagen)用高危和低危探针进行 HPV 检测,并使用 Linear Array(Roche)进行 HPV 基因分型。
约 11%的研究人群存在细胞学异常(ASCUS 或更差)。整个研究人群的 HPV 流行率为 14.3%(按世界标准女性人群 14.5%标准化)。发现最常见的类型是 HPV16(2.9%)、HPV52(1.7%)、HPV58(1.5%)、HPV33(1%)和 HPV18(0.8%)。HPV 流行率的模式因年龄、地理区域和细胞学发现而异。然而,HPV16 在所有细胞学异常程度中均占主导地位。
尽管 HPV18 在基于人群的中国样本中似乎不太常见,但鉴于 HPV16 和 18 在高级别鳞状上皮内病变(HSIL)或更差的巴氏异常中普遍存在,预防性 HPV16/18 疫苗应可大大减轻中国宫颈癌的负担。